Piflufolastat F 18 is a radiopharmaceutical diagnostic agent used with PET to image PSMA-positive lesions for the diagnosis of metastatic or recurrent prostate cancer. Prostate cancer is the most common non-cutaneous malignancy affecting men in North America - despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent and location of tumor metastases...
- Mechanism
- Curator reviewed · 2 references
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that plays a role in dietary folate uptake and the release of neurotransmitters within the brain. While PSMA is expressed in many tissues, its expression levels in the prostate are roughly 1000-fold greater than elsewhere in the body and even higher in prostate cancer tissue.
Piflufolastat F18 binds to PSMA and therefore, in combination with PET imaging, allows for the visualization of PSMA-positive lesions associated with prostate cancer.
- Primary indication
- Piflufolastat F18 is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer who have suspected metastases and are candidates for initial definitive therapy and for men...Curator reviewed · 4 structured indications
- Formula / weight
- C18H23FN4O8 · 441.403 g/mol (avg)
- First approval
- United States, 2021 · European Union, 2023
- Also known as
- (18F)DCFPyL · [18F]DCFPyL · [F-18] DCFPyL · [F-18]-DCFPyL · 18F-DCFPyL
- Brand names
Resolves to
OLWVRJUNLXQDSP-MVBOSPHXSA-NSMILESOC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C([18F])N=C1)C(O)=O)C(O)=OWhat you can answer from here — as of September 21, 2026
Which drugs share a target with Piflufolastat F 18, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account